CDC Updates Advisory Committee Recommendations for Influenza Vaccination Coverage

CDC Updates Advisory Committee Recommendations for Influenza Vaccination Coverage

The Centers for Disease Control and Prevention published its 2024–25 influenza vaccine recommendations on August 22, 2024, drawing directly from the Advisory Committee on Immunization Practices (ACIP). The report reaffirms that annual vaccination is recommended for all people aged 6 months and older who lack contraindications, while updating the specific influenza virus strains included in this season’s vaccines [1]. These changes align U.S. formulations with global surveillance data compiled by the World Health Organization and reflect the vaccines newly licensed by the Food and Drug Administration for the upcoming season [2][3].

The guidance arrives as public health agencies prepare for the overlap of respiratory virus seasons, when influenza circulates alongside COVID-19 and RSV. By documenting both the universal recommendation and the precise viral components selected, the CDC document offers a transparent snapshot of how strain surveillance translates into vaccine policy.

What this means

The updated strain selection reflects continuous global monitoring of circulating viruses and the need to adjust vaccine content each year. The absence of a preferential recommendation for any specific product or brand indicates that multiple licensed options are viewed as acceptable when medically appropriate for an individual. For populations that consistently show higher rates of severe illness, the report restates that vaccination remains associated with reduced risk, though effectiveness depends on the match between vaccine strains and those that ultimately spread.

Universal Recommendation Remains in Place

The CDC report states that all persons aged ≥6 months without contraindications should receive annual influenza vaccination [1]. This language mirrors previous seasons and underscores the committee’s view that routine immunization forms a central part of seasonal respiratory virus preparedness. The recommendation applies across age groups and does not single out one demographic as the sole target.

Updated Virus Strains Selected for 2024–25

For trivalent vaccines, the 2024–25 formulation includes an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus [1][3]. These components were chosen following WHO consultations that reviewed virologic and epidemiologic data from laboratories worldwide [3]. The FDA has confirmed that all influenza vaccines licensed for the 2024–2025 season incorporate these updated strains [2].

No Preferential Recommendation for Vaccine Type or Brand

The ACIP document finds no preference for any particular influenza vaccine type or brand when more than one licensed product is appropriate for a given person [1]. This stance covers egg-based, cell-culture, recombinant, and adjuvanted options, allowing flexibility for providers and patients based on availability, storage requirements, and individual medical history.

Guidance for Children, Pregnant Persons, and Older Adults

The report notes that young children, pregnant persons, older adults, and those who are immunocompromised derive substantial benefit from vaccination, consistent with patterns observed in prior seasons [1]. It does not introduce new product-specific directives for these groups beyond the general principle that any appropriate licensed vaccine may be used. The language emphasizes that clinical judgment remains necessary when weighing individual risk factors.

Coadministration with Other Respiratory Vaccines

The CDC guidance states that influenza vaccines may be given at the same time as COVID-19 or RSV vaccines [1]. This aligns with broader recommendations on simultaneous administration of routinely recommended vaccines and acknowledges the practical reality that multiple immunizations may be due during a single health care visit.

Limitations

These recommendations are specific to the United States and apply only to the 2024–2025 influenza season. Vaccine effectiveness varies each year depending on how closely the selected strains match those that circulate [1]. The evidence does not replace individualized clinical judgment and cannot predict outcomes for any single person. Data on real-world effectiveness for the current season will not be available until after the viruses have spread.